Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares

Key Points

• Jason Drew Smith, General Counsel of Urogen Pharma, sold 1,520 shares at an average price of $19.11, resulting in a 3.39% decrease in his holdings.
• Urogen Pharma reported a quarterly loss of ($1.05) EPS, missing analysts' expectations, despite revenue of $24.22 million.
• Analyst ratings for Urogen Pharma are predominantly positive, with an average price target of $32.00 and some firms maintaining a buy or outperform rating on the stock.

Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 1,520 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the transaction, the general counsel owned 43,305 shares in the company, valued at approximately $827,558.55. This represents a 3.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jason Drew Smith also recently made the following trade(s):

• On Monday, July 28th, Jason Drew Smith sold 7,522 shares of Urogen Pharma stock. The shares were sold at an average price of $19.14, for a total value of $143,971.08.

Urogen Pharma Trading Down 2.4%

Urogen Pharma stock traded down $0.46 during mid-day trading on Friday, hitting $18.79. The stock had a trading volume of 886,418 shares, compared to its average volume of 1,085,832. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $21.71. The stock has a market capitalization of $869.23 million, a PE ratio of -5.66 and a beta of 1.10. The stock has a 50-day simple moving average of $18.19 and a two-hundred day simple moving average of $12.90.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The company had revenue of $24.22 million for the quarter, compared to the consensus estimate of $23.06 million. Sell-side analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on URGN shares. Piper Sandler started coverage on Urogen Pharma in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price on the stock. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. Wall Street Zen upgraded Urogen Pharma from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim reiterated a "buy" rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Finally, Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Urogen Pharma has a consensus rating of "Buy" and a consensus target price of $32.00.

Hedge Funds Weigh In On Urogen Pharma

Several institutional investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after purchasing an additional 2,983,368 shares in the last quarter. RTW Investments LP lifted its stake in Urogen Pharma by 1.3% in the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after acquiring an additional 47,447 shares in the last quarter. RA Capital Management L.P. bought a new stake in Urogen Pharma in the 1st quarter valued at approximately $35,461,000. Soleus Capital Management L.P. bought a new stake in Urogen Pharma in the 2nd quarter valued at approximately $29,934,000. Finally, Vestal Point Capital LP lifted its stake in Urogen Pharma by 32.1% in the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock valued at $23,812,000 after acquiring an additional 522,957 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.